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Microsomal prostaglandin E synthase-1 in rheumatic diseases
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Microsomal prostaglandin E synthase-1 (mPGES-1) is a well-recognized target for the development 
of novel anti-inflammatory drugs that can reduce symptoms of inflammation in rheumatic 
diseases and other inflammatory conditions. In this review, we focus on mPGES-1 in rheumatic 
diseases with the aim to cover the most recent advances in the understanding of mPGES-1 
in rheumatoid arthritis, osteoarthritis, and inflammatory myopathies. Novel findings regarding 
regulation of mPGES-1 cell expression as well as enzyme inhibitors are also summarized.
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Rheumatoid aRthRitis
In patients with RA, the PGE2 levels in the synovial fluid are mark-
edly elevated (Punzi et al., 1989), and both activated synovial tis-
sue cells and recruited synovial fluid cells might contribute to the 
release of PGE2 into the synovial fluid. Indeed, mPGES-1 is mark-
edly expressed in RA synovial tissue (Westman et al., 2004) and 
even stronger up-regulated in patients with active than with inactive 
RA (Murakami et al., 2003). Within the synovial tissue, mPGES-1 
was mainly localized to the synovial lining cells (Figure 2A). High 
expression was also found in sublining layer in scattered mononu-
clear fibroblast-like cells, mononuclear infiltrates and endothelial 
cells of some blood vessels. Phenotypic analysis using immunofluo-
rescence also demonstrated that mPGES-1 was expressed in synovial 
fibroblasts and macrophages, the abundant cell populations present 
in hyperplastic RA synovial tissue. No expression of mPGES-1 was 
observed in T or B lymphocytes (Westman et al., 2004).
The distribution pattern of mPGES-1 positive cells largely 
reflects the localization of Cox-2 positive cells in RA synovial tis-
sue. As demonstrated with double immunofluorescence, mPGES-1 
and Cox-2 were co-localized in cells of the synovial lining layer and 
sublining cells and in synovial fluid mononuclear cells (Korotkova 
et al., 2005). The colocalization of these enzymes has been reported 
in the same subcellular compartments, the perinuclear membrane, 
and endoplasmic reticulum (Murakami et al., 2000; Lazarus et al., 
2002), which provides basis for the preferred functional coupling 
between mPGES-1 and Cox-2 (Murakami et al., 2000; Thoren and 
Jakobsson, 2000) although Cox-1 may also serve as provider of 
PGH2 in some situations (Dieter et al., 2000; Murakami et al., 2000). 
This focused up-regulation of mPGES-1 and Cox-2 in RA synovial 
cells is probably the cause of the abundant PGE2 biosynthesis in the 
joints in turn contributing to inflammatory and destructive proc-
esses. Interestingly, studies in vitro and in experimental arthritis 
model have reported that cytosolic phospholipase A2 (cPLA2), that 
intRoduction
Microsomal prostaglandin E synthase-1 (mPGES-1) catalyzes the 
glutathione dependent oxidoreduction of prostaglandin H2 into 
PGE2 (Jakobsson et al., 1999; Pettersson et al., 2005; Figure 1).
The substrate for mPGES-1, prostaglandin endoperoxide H2 
(PGH2) is generated by cyclooxygenase (Cox)-1 or 2 by oxidation 
of arachidonic acid in turn released from phospholipids by vari-
ous phospholipases. PGH2 is also converted to PGE2 by two other 
enzymes, cytosolic PGES (cPGES) and mPGES-2, structurally and 
biologically distinct from mPGES-1 (Murakami et al., 2002; Tanioka 
et al., 2003). During inflammation the prostaglandin cascade is 
activated by calcium signaling and cytokine dependent enzyme 
inductions. In particular, Cox-2 and mPGES-1 are rapidly induced 
within hours by pro-inflammatory cytokines in macrophages and 
fibroblasts (Murakami et al., 2000; Stichtenoth et al., 2001). In many 
situations this cellular activation results in significant increase of 
PGE2 biosynthesis. PGE2 mediates its effects via G-protein coupled 
receptors EP1 to EP4. If produced via mPGES-1, PGE2 usually 
causes inflammation including swelling, fever and inflammatory 
pain (Engblom et al., 2003; Trebino et al., 2003; Kamei et al., 2004), 
while cPGES or mPGES-2 seems to constitutively produce PGE2 
possibly important for physiological reactions (Murakami et al., 
2003; Tanioka et al., 2003). Therefore, mPGES-1 is today a well- 
recognized target for the development of novel anti-inflammatory 
drugs that can reduce symptoms of inflammation in rheumatic 
diseases and other inflammatory conditions, hopefully without 
causing stomach ulcerations or severe cardiovascular side effects 
as traditional non-steroidal anti-inflammatory drugs (NSAIDs) 
or selective Cox-2 inhibitors may do (Samuelsson et al., 2007). In 
this review, we focus on mPGES-1 in rheumatic diseases with the 
aim to cover the most recent advances in the understanding of 
mPGES-1 in rheumatoid arthritis (RA), osteoarthritis (OA), and 
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sublining cells, and the staining pattern was similar in RA patients 
despite different pathological states (Murakami et al., 2003). The 
presence of the housekeeping cPGES and mPGES-2 in RA syno-
vial tissue implies that they might produce PGE2 required for the 
maintenance of homeostasis.
In order to better understand what mechanisms regulate the 
overexpression of Cox and mPGES-1 in RA we have studied 
the effects of anti-rheumatic drugs. Intra-articular treatment of 
patients with glucocorticoids significantly reduced mPGES-1 as 
well as both Cox-1 and Cox-2 expression in arthritic synovial tissue 
ex vivo. In contrast, treatment of RA patients with TNF blockers 
did not suppress either mPGES-1 or Cox expression in synovial 
tissues, implying that other mechanisms function in sustaining the 
inflammation independently of TNF (Korotkova et al., 2005).
In vItro Regulation of mPges-1 exPRession in cells  
fRom Ra joint
The results of in vitro experiments have provided convincing 
evidence that the expression of mPGES-1 in RA joints might be 
up-regulated by a wide range of stimuli. Initially, the induction of 
mPGES-1 was demonstrated in response to the pro-inflammatory 
cytokines IL-1β, TNF, or LPS. In synovial fluid mononuclear cells 
isolated from RA patients, the expression of mPGES-1 and Cox-2 
was substantially up-regulated in response to LPS and accompa-
nied by enhanced PGE2 release (Korotkova et al., 2005). Treatment 
of RA synovial fibroblasts with IL-1β and TNF in vitro caused 
a coordinated up-regulation of mPGES-1 and Cox-2 with con-
comitant abundant PGE2 production, but there was no effect on 
cPGES expression (Stichtenoth et al., 2001; Kojima et al., 2002). 
Moreover, the early release of PGE2 from these cells may further 
increase the expression of mPGES-1 via an autocrine positive 
feed-back loop (Kojima et al., 2003). In addition, in rodent pri-
mary osteoblasts mPGES-1 and Cox-2 were strongly induced by 
bone resorptive cytokines IL-1β and TNF, as well as by fibroblast 
growth factor 2 (FGF-2) and LPS, resulting in an enhanced bio-
synthesis of PGE2. This suggests that cytokine-induced mPGES-1 
may be a potent regulator of bone resorption in RA via PGE2 
production (Murakami et al., 2000; Saegusa et al., 2003; Inada 
et al., 2006).
Recent studies have elucidated additional mechanisms involved 
in regulation of mPGES-1 expression in the RA joint. Epidermal 
growth factor (EGF) is constitutively produced by RA synovial 
fibroblasts and found in the synovial fluid of RA patients at high 
levels (Bucala et al., 1991; Kusada et al., 1993). EGF stimulates 
the release of inflammatory mediators and the growth of synovial 
cells suggesting its involvement in the pathogenesis of this dis-
ease (Kusada et al., 1993; Satoh et al., 2001). EGF increases both 
Cox-2 and mPGES-1 mRNA expression in synovial fibroblasts 
from RA patients and induces PGE2 production via the ERK1/
MAPK and NFkB pathways (Nah et al., 2010). Another molecule 
that contributes to mPGES-1 up-regulation is adiponectin, one of 
the adipokines produced by fat cells. Adiponectin is strongly up-
regulated in synovial fluid and synovial tissue from RA patients 
and exerts significant pro-inflammatory effects (Ehling et al., 
2006). Interestingly, RA synovial fibroblasts exposed to adiponec-
tin released high amounts of PGE2 by induction of the enzymes 
mPGES-1 and Cox-2 (Kusunoki et al., 2010).
supplies arachidonic acid to downstream Cox, is also activated in 
arthritic tissue and the activity showed a correlation with severity 
of the arthritis (Hulkower et al., 1994; Tai et al., 2010).
The expression of cPGES was also observed in synovial lining 
cells, sublining mononuclear and fibroblast-like cells, mononu-
clear infiltrates, and some blood vessels (Westman et al., 2004). The 
staining for mPGES-2 revealed its expression in synovial lining and 
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FigurE 1 | Biosynthesis of prostaglandin E2. Cyclooxygenase (Cox)-1 or 2 
produce PGH2 that can be converted into PGE2 by mPGES-1. Alternatively, 
mPGES-2 or cytosolic PGES catalyze the same reaction and likely such PGE2 
is more involved in physiological reactions. Different cells produce distinct 
prostaglandin profiles which reflect their expression profiles of specific 
prostaglandin synthases. For instance, endothelial cells produce both PGE2 
and PGI2 whereas platelets predominantly produce TXA2.
FigurE 2 | immunohistochemical staining (brown) for microsomal PgES 
(mPgES)-1 in representative (A,B) synovial tissue from RA patients, (C) 
synovial tissue from OA patient and (D) in muscle tissue from a patient with 
polymyositis. Original magnification ×250 (A) and ×500 (B–D).www.frontiersin.org  January 2011  | Volume 1  |  Article 146  |  3
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elucidated. There is evidence that PGE2 promotes its own  synthesis 
in the synoviocytes by stabilization of Cox-2 mRNA (Faour et al., 
2001) and by increased mPGES-1 expression (Kojima et al., 2003). 
Hence, suppression of induced PGE2 biosynthesis by NSAID 
potentially might prevent further up-regulation of mPGES-1 and 
Cox-2 expression via inhibition of this autocrine positive feed-
back loop.
Treatment of chondrocytes or synovial fibroblasts from OA 
patients with the pro-inflammatory cytokine IL-1β results in a 
strong induction of mPGES-1 and increased release of PGE2 
(Cheng et al., 2004; Masuko-Hongo et al., 2004; Li et al., 2005). 
TNF and IL-17 also up-regulate mPGES-1 expression in chondro-
cytes, though less potently, whereas other cytokines, such as IL-4, 
IL-6, IL-8, IL-10, and IFNg have no effect (Kojima et al., 2004; 
Li et al., 2005). Interestingly, at low levels (0.1 pg/ml–0.5 ng/ml) 
the cytokines IL-1β, TNF, and IL-17 alone show little effect on 
mPGES-1 expression and PGE2 production. However, the combina-
tion of these cytokines at low concentrations displayed synergistic 
effects on mPGES-1 expression in OA chondrocytes. In contrast, 
the levels of cPGES and mPGES-2 were not changed by these treat-
ments (Li et al., 2005).
Similarly to RA, several other factors besides the pro-inflam-
matory cytokines are implicated in the induction of mPGES-1 in 
the OA joint. The increase of mPGES-1 expression in OA cartilage 
is at least partly related to hypoxia and activity of hypoxia acti-
vated factor 1α (HIF1α; Grimmer et al., 2007). Advanced glycation 
end products (AGEs) extensively accumulate in cartilage collagen 
with age and predispose to the development of OA (DeGroot et al., 
2004). Nah et al. (2008) have shown that treatment of primary 
human OA chondrocytes with AGE induces mPGES-1 and Cox-2 
expression and elevates PGE2 production.
Recently a possible link between OA and obesity has been shown 
in several studies, highlighting the critical role of mechanical load-
ing and the potential role of adipokines in cartilage degradation 
(Pottie et al., 2006; Gosset et al., 2008). Interestingly, both mechani-
cal loading and some adipokines have been demonstrated to induce 
mPGES-1 in cartilage. The mechanical compression of mouse 
cartilage explants significantly elevated PGE2 release, which was 
associated with induced Cox-2 and mPGES-1 expression. Thus, 
both Cox-2 and mPGES-1 are encoded by mechanosensitive genes 
and implicated in compression-induced PGE2 production (Gosset 
et al., 2006). Adipose tissue cells secrete a number of adipokines, 
proteins with the structural and functional properties of cytokines, 
which possess potent pro-inflammatory and pro-degradative 
effects and might contribute to OA progression (Pottie et al., 2006). 
A newly identified adipokine visfatin potently induces mPGES-1 
and suppresses 15-PGDH expression, leading to enhanced PGE2 
production by human and mouse articular chondrocytes (Gosset 
et al., 2008).
inflammatoRy myositis
The expression and localization of mPGES-1 and other enzymes 
related to PGE2 biosynthetic pathway were also examined in 
muscle tissue from patients with polymyositis or dermato-
myositis. A significantly enhanced expression of mPGES-1 
(Figure 2D), Cox-2, and Cox-1 was detected in myositis mus-
cle tissue compared to healthy muscle tissue, suggesting their 
Recently, a direct role in inflammation and joint   destruction 
in RA was suggested for microparticles, abundantly present 
in the synovial fluid of inflamed joints (Distler et al., 2005). 
Microparticles are small membrane-coated vesicles released from 
activated or dying cells by exocytic budding and display surface 
proteins from their parental cells. Microparticles derived from 
leukocytes strongly induced mPGES-1 and Cox-2 expression in 
RA synovial fibroblasts thereby stimulating the production of PGE2 
(Jungel et al., 2007).
The induction of mPGES-1 is markedly suppressed by anti-
inflammatory glucocorticoids. In studies examining RA syno-
vial fibroblasts, synovial fluid monocytes, and OA chondrocytes, 
treatment with dexamethasone (Dex) decreased mPGES-1 
mRNA, protein expression, and enzyme activity induced by pro-
inflammatory stimuli in dose-dependent manner (Stichtenoth 
et al., 2001; Kojima et al., 2002; Korotkova et al., 2005; Shimpo 
et al., 2009). However, the inhibition of mPGES-1 by Dex was 
weaker compared with that of Cox-2 in IL-1ß stimulated RA 
synovial fibroblasts (Kojima et al., 2002). Interestingly, in OA 
chondrocytes, PGE2 recovered mPGES-1 expression from sup-
pression by Dex, whereas it did not restore the expression of 
Cox-2 in the presence of Dex (Shimpo et al., 2009). These 
results suggest that different mechanisms might be involved 
in the inhibition of mPGES-1 and Cox-2 by glucocorticoids. 
Glucocorticoids suppress Cox-2 expression both by transcrip-
tional (via inhibition of transcription factors such as AP-1 and 
NF-κB) and post-transcriptional mechanisms involving mRNA 
destabilization (Newton et al., 1998). The inhibitory effect of 
Dex on mPGES-1 expression may be at least partly explained 
by suppression of the NFkB and AP-1, playing a role in induc-
tion of mPGES-1 (Jungel et al., 2007). In addition, the putative 
promoter of the mouse mPGES-1 gene contains three glucocor-
ticoid response elements that may regulate mPGES-1 expression 
(Naraba et al., 2002). However, further studies are required to 
better define the molecular mechanisms of mPGES-1 suppres-
sion by glucocorticoids.
osteoaRthRitis
In patients with OA, cartilage spontaneously releases more 
PGE2 than normal cartilage (Amin et al., 1997). In OA cartilage 
mPGES-1 mRNA and protein levels are markedly elevated com-
pared to the normal cartilage, and mPGES-1 immunostaining 
demonstrates that mPGES-1 is located in the chondrocytes of 
OA cartilage and the synovial lining cells of OA synovial tissue 
(Kojima et al., 2004, 2005; Li et al., 2005). We have also detected 
mPGES-1 expression in OA synovial lining layer and sublining 
cells (Gheorghe, unpublished observation, Figure 2). Thus, over-
expression of mPGES-1 in OA synovial tissue and cartilage might 
contribute to chronic inflammation, pain, and catabolic processes 
related to OA.
Long-term treatment with traditional NSAIDs or selective 
Cox inhibitors decreases PGE2 production in OA cartilage via 
direct inhibition of Cox activity and suppression of Cox-2 and 
mPGES-1 expression. In cultured chondrocytes, NSAIDs inhibit 
IL-1β-induced mPGES-1, Cox-2 expression, and PGE2 synthesis 
(Alvarez-Soria et al., 2008). The mechanisms behind the inhibi-
tion of mPGES-1 and Cox-2 expression by NSAID are not entirely Frontiers in Pharmacology | Inflammation Pharmacology    January 2011  | Volume 1  |  Article 146  |  4
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The severity of collagen antibody-induced arthritis was also 
lower in mPGES-1 KO mice relatively to WT mice and associated 
with milder cartilage degeneration and lower bone resorption likely 
due to the reduced number of osteoclasts (Kamei et al., 2004). 
The critical role of mPGES-1 for bone losses related to inflam-
mation was confirmed in mice. In WT mice, LPS administration 
resulted in reduced bone density and thickness and increased bone 
resorption associated with enhanced number of osteoclasts, while 
mPGES-1 KO mice were resistant to such LPS-induced bone loss 
(Inada et al., 2006).
Thus, targeting mPGES-1 in arthritic mice reduces inflamma-
tion, humoral immune response, and protects them from pain 
and joint destruction, replicating many of the favorable anti-in-
flammatory effects by traditional NSAIDs and Cox-2 inhibitors. 
Furthermore, Cox-2 has an important role in the resolution of 
inflammation via generation of anti-inflammatory eicosanoids like 
15-deoxy-∆12,14-PGJ2, resolvins, and protectins, and its inhibi-
tion within this period might propagate inflammation. Moreover, 
although PGE2 is a classic promoter of inflammation, some anti-
inflammatory and pro-resolving effects of PGE2 have also been 
reported (Gomez et al., 2005; Chan and Moore, 2010). Therefore, 
it is important to examine whether mPGES-1 is the source of PGE2 
during the resolution phase of inflammation.
Interestingly, a different expression profile of Cox-2 and mPG-
ES-1 was detected during the resolution phase of normal wound 
repair (Kapoor et al., 2007). Following the up-regulation during 
the inflammation phase, the expression of mPGES-1 dropped rap-
idly to the basal levels during the resolution phase, while Cox-2 
expression was maintained throughout the initiation and repair 
processes. In mice with CIA, blocking Cox-2 during the resolution 
phase perpetuated inflammation resulting in increased destruction 
of the joints (Chan and Moore, 2010). In contrast, mPGES-1 was 
restricted to the inflammation phase, suggesting that mPGES-1 
inhibition may possibly be able to limit the severity of inflammation 
without interfering with resolution of arthritis (Chan and Moore, 
2010). However, further investigation is needed to establish that 
mPGES-1 does not affect the resolution process.
It was suggested that selective blockage of mPGES-1 would also 
avoid the typical for NSAIDs adverse side effects such as the quite 
common GI side effects or the severe but less common cardiovas-
cular side effects. Indeed, genetic deletion of mPGES-1, in contrast 
to deletion, disruption, or pharmacological inhibition of Cox-2, did 
not result in accelerated thrombogenesis or elevated blood pressure 
in normolipidemic mice (Cheng et al., 2006). Furthermore, lack 
of mPGES-1 delayed atherosclerosis development and attenuated 
aortic aneurysm formation in hyperlipidemic mice with genetic 
deletion of the receptor for low density lipoprotein (LDLR −/−; 
Wang et al., 2006, 2008).
Another concern is the effect of NSAIDs and mPGES1 inhibition 
on the blood pressure. Several studies have shown that blood pres-
sure was similar in mPGES1-deficient and WT mice on control or 
high- or low-salt diets (Cheng et al., 2006; Francois et al., 2007) and 
in response to infusion of angiotensin II (Wang et al., 2008). In con-
trast, other studies have demonstrated that blockage of mPGES-1 
augmented hypertensive response to high-salt feeding or infusion 
of angiotensin II in mice (Jia et al., 2006, 2008). This discrepancy 
probably reflects the differences in genetic background of mice 
role in the   pathogenesis of inflammatory myositis. Double 
 immunofluorescence  demonstrated a predominant expression of 
mPGES-1 in macrophages (Korotkova et al., 2008). Conventional 
immunosuppressive  treatment of  myositis patients with oral glu-
cocorticoids and DMARDs led to a significant down-regulation 
of Cox-2 while mPGES-1 expression in inflamed muscle was not 
affected (Korotkova et al., 2008). The divergent effects of the treat-
ment on Cox-2 and mPGES-1 expression may be explained by the 
differences in the mechanisms of glucocorticoid actions on the 
enzymes. In addition, the suppression of mPGES-1 may require 
higher glucocorticoid concentration, as previously observed 
after intra-articular treatment with high doses of glucocorticoids 
(Korotkova et al., 2005).
Taken together, these studies demonstrate that mPGES-1 is 
strongly up-regulated in rheumatic diseases by a variety of stimuli. 
Thus, the inhibition of PGE2 biosynthesis, preferably by targeting 
mPGES-1, might act synergistically with different anti-rheumatic 
therapies for optimal anti-inflammatory control.
lessons fRom exPeRimental models in Rodents
The important role of mPGES-1 as a novel therapeutic target 
for treatment of RA was further strengthened in experimental 
models of arthritis. A strong up-regulation of mPGES-1 mRNA 
and protein levels was demonstrated in the inflamed paws of 
rats with adjuvant-induced arthritis during the full course of 
the disease (Mancini et al., 2001; Claveau et al., 2003). Moreover 
in arthritic rats mPGES-1 was also induced in endothelial cells 
along the blood–brain barrier and the paraventricular nucleus 
of the hypothalamus suggesting the involvement of mPGES-1 in 
the activation of the central nervous symptoms associated with 
chronic autoimmune disease (Engblom et al., 2002a). Centrally 
produced PGE2 binds EP receptors present on relevant deep 
neural structures and elicits the central nervous illness response 
such as fever, fatigue, anorexia–cachexia, hyperalgesia, and dys-
regulation of the hypothalamus–pituitary adrenal axis (Engblom 
et al., 2002b).
Generation of mice with genetic deletion of mPGES-1 
(mPGES-1 KO) has provided valuable insights into the role of 
mPGES-1 in inflammatory arthritis. In mPGES-1 KO mice the 
incidence of collagen-induced arthritis (CIA), as well as specific 
parameters of arthritis severity including synovial hyperplasia, 
infiltration of inflammatory cells, cartilage destruction, and 
bone erosion were significantly reduced compared with those 
in wild type (WT) mice (Trebino et al., 2003; Kojima et al., 2008). 
Moreover, during the development of CIA, pain perception after 
mechanical stimulation was significantly reduced in mPGES-1 
KO mice compared to that in WT mice (Kojima et al., 2008). The 
reduction in observed inflammatory features in mPGES-1 KO 
mice was also associated with significantly lower serum levels of 
anti-collagen II antibody and reduced levels of total IgG and IgM 
(Kojima et al., 2008). The decreased antibody response seen in 
mPGES-1 KO mice was not due to impairment of T cell and B 
cell numbers or functions. It has been suggested that mPGES-1 
deficiency and reduced PGE2 may result in an altered cytokine 
profile and tissue environment in which antigen-presenting cells 
encounter antigen and interact with T cells and B cells (Kojima 
et al., 2008).www.frontiersin.org  January 2011  | Volume 1  |  Article 146  |  5
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synthesized at Pfizer, Inc. (St. Louis, MO, USA), is another potent 
and selective inhibitor of human mPGES-1 from an oxicam series 
(IC50 of 16.5 nM) and shows low potency against rat mPGES-1. 
PF-9184 decreased PGE2 biosynthesis by RA synovial fibroblasts 
induced with IL-1β for 24 h. In addition, unexpected inhibition 
of the prostacyclin metabolite 6-keto PGF1a was detected, presum-
ably due to interference with feed-back mechanisms on Cox-2 
 expression  (Mbalaviele et al., 2010). At experimental conditions 
analyzing a direct effect of this inhibitor on mPGES-1 activity, 
PF-9184 significantly suppressed PGE2 generation, while shunt-
ing PGH2 into PGI2 and PGF2a pathways respectively (Mbalaviele 
et al., 2010).
MF63, a lead compound from a series of phenanthrene imida-
zole inhibitors made by Merck Frost, Quebec, Canada, is a selec-
tive inhibitor of mPGES-1 with high degree of selectivity over 
mPGES-2, PGI2, PGD2, and thromboxane (TX) synthases, Cox-1, 
Cox-2, 5-lipoxygenase, and various prostanoid and leukotriene 
receptors. It is potent inhibitor of human (IC50 of 1.3 nM) and 
guinea pig (IC50 of 0.9 nM) mPGES-1, but displays little activity 
toward the rat or mouse enzyme (Xu et al., 2008). Therefore in vivo 
efficacy of MF63 was evaluated in a knock-in (KI) mouse, express-
ing human mPGES-1 as well as in guinea pig. In the KI mouse, 
MF63 selectively suppressed PGE2, but not other prostanoids in 
LPS-induced air pouch model and inhibited LPS-induced hyperal-
gesia by 50% at 10 mg/kg and 80% at 100 mg/kg. In the guinea pig, 
MF63 strongly inhibited LPS-induced pyresis and hyperalgesia and 
relieved chronic osteoarthritic pain at 30–100 mg/kg. Under these 
concentrations MF63 did not cause gastrointestinal toxic effects in 
the KI mouse and non-human primates (Xu et al., 2008).
The inter-species differences of inhibitor potencies make it 
more difficult to evaluate if a human enzyme inhibitor have tar-
get or off-target effects in relevant animal models. The 3D struc-
ture of mPGES-1 revealed that the active surface falls in between 
transmembrane helices one and four of neighboring monomers 
(Jegerschold et al., 2008). Recently we demonstrated the combined 
role of three individual amino acids, different among human 
and mice/rat mPGES-1 located in transmembrane helix 4, that 
together accounted for most of the observed species difference for 
the utilized mPGES1 inhibitor (Pawelzik et al., 2010). Thus, this 
could pose a problem in the development of mPGES-1 inhibitors. 
However, as also demonstrated inhibitors with potencies to both 
rodent and human species exist (Pawelzik et al., 2010).
conclusion
mPGES-1 constitutes a novel target for anti-inflammatory drugs. 
The enzyme is overexpressed in RA, OA, and myositis. Anti-
rheumatic drugs including TNF blockers or oral glucocorticoids 
are ineffective in down-regulating this enzyme suggesting that local 
inflammation persists while the overall symptoms are under con-
trol. The latter finding also suggests that combination therapies 
of biologicals and mPGES1 inhibitors may be more effective than 
single therapies. Inhibitors against mPGES-1 are being developed 
by several laboratories but so far no clinical trial data have been 
reported. The suitability of mPGES-1 as a drug target and the pros 
and cons comparing with Cox inhibition is a rather complex matter 
and not discussed in details in this review. In short, one may state 
that mice devoid of mPGES-1 display fewer or milder   phenotypes 
which significantly influence the generation of other vasoactive 
prostanoids and blood pressure response to mPGES-1 deficiency 
(Facemire et al., 2010).
Deficiency in mPGES-1 and reduced PGE2 formation may 
also have unfavorable effects on the cardiac response to myo-
cardial infarction (MI). Lack of mPGES-1 resulted in eccentric 
  cardiomyocyte hypertrophy and compromised the left ventricu-
lar remodeling after acute MI in mice resulting in a mild heart 
failure. In contrast, cardiac mass, infarct size, and mortality after 
MI were similar in mPGES-1 KO and WT mice (Degousee et al., 
2008). However, no head to head comparisons have been per-
formed comparing Cox-2 KO with mPGES-1 KO mice in this 
model. In line, compared to genetic deletion of mPGES-1 the 
treatment of WT mice with Cox-2 inhibitor celecoxib exerted an 
increased cardiac risk under acute ischemia condition augment-
ing myocardial injury and reducing post-MI survival (Wu et al., 
2009). The results suggested that selective inhibition of mPGES-1 
derived PGE2 but not other PGs suppressible by Cox-2 inhibitors 
might have reduced cardiac risk compared to selective inhibition 
of Cox-2 (Wu et al., 2009).
However, it remains to be investigated whether selective phar-
macological inhibition of mPGES-1 will result in the same effects 
as conferred by mPGES-1 gene deletion studies. Direct comparisons 
with Cox-2 inhibitors will also provide important insights about the 
relative and putative side effects elicited by mPGES1 inhibition.
mPges-1 inhibitoRs
Several selective inhibitors of mPGES-1 activity or expression have 
been identified and some of them have been evaluated in different 
inflammatory models (Xu et al., 2008; Guerrero et al., 2009; Bruno 
et al., 2010; Mbalaviele et al., 2010). The inhibitor of mPGES-1 
expression, BTH (4-benzo[b]thiophen-2-yl-3-bromo-5-hydroxy-
5H-furan-2-one) synthesized at Departamento de Farmacologia, 
Universitat de Valencia, Spain, was studied in acute and chronic 
inflammatory models (mouse air pouch and CIA, respectively; 
Guerrero et al., 2009). In mouse air pouch exudates, BTH sup-
pressed PGE2 production via down-regulation of mPGES-1 expres-
sion without any effect on Cox-1 and Cox-2 expression or activity. 
Treatment of mice with BTH strongly reduced CIA incidence 
and alleviated severe arthritis, diminishing the inflammatory cell 
infiltration, cartilage erosion, and proteoglycan loss. These clini-
cal effects were associated with reduced mPGES-1 expression and 
suppressed PGE2 production in paw homogenates. The inhibitory 
effect of BTH on mPGES-1 expression can be partly explained by its 
inhibitory action on the activation of NFkB (Guerrero et al., 2007), 
which might contribute to suppression of other pro-inflammatory 
mediators and needs to be elucidated, thus the selectivity of this 
compound must be questioned.
Among selective inhibitors of mPGES-1 enzyme activity, two 
inhibitors have been evaluated in cell-based systems relevant to 
RA, i.e., human monocytes and synovial fibroblasts (Bruno et al., 
2010; Mbalaviele et al., 2010). AF3442, a lead compound from a 
series of carbazole benzamides synthesized in Angelini Research 
Center, Rome, Italy, is a potent inhibitor of human mPGES-1 activ-
ity (IC50 of 0.06 μM). In LPS-induced human monocytes AF3442 
significantly reduced PGE2 formation without redirection of PGH2 
metabolism to other prostanoids (Bruno et al., 2010). PF-9184, Frontiers in Pharmacology | Inflammation Pharmacology    January 2011  | Volume 1  |  Article 146  |  6
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